Welcome to The Visible Embryo

Home- - -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- News Alerts -Contact

Welcome to The Visible Embryo, a comprehensive educational resource on human development from conception to birth.

The Visible Embryo provides visual references for changes in fetal development throughout pregnancy and can be navigated via fetal development or maternal changes.

The National Institutes of Child Health and Human Development awarded Phase I and Phase II Small Business Innovative Research Grants to develop The Visible Embryo. Initally designed to evaluate the internet as a teaching tool for first year medical students, The Visible Embryo is linked to over 600 educational institutions and is viewed by more than ' million visitors each month.


WHO International Clinical Trials Registry Platform
The World Health Organization (WHO) has created a new Web site to help researchers, doctors and patients obtain reliable information on high-quality clinical trials. Now you can go to one website and search all registers to identify clinical trial research underway around the world!



Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

Contact The Visible Embryo

News Alerts Archive

Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.
Content protected under a Creative Commons License.

No dirivative works may be made or used for commercial purposes.

Return To Top Of Page
Pregnancy Timeline by SemestersFemale Reproductive SystemFertilizationThe Appearance of SomitesFirst TrimesterSecond TrimesterThird TrimesterFetal liver is producing blood cellsHead may position into pelvisBrain convolutions beginFull TermWhite fat begins to be madeWhite fat begins to be madeHead may position into pelvisImmune system beginningImmune system beginningPeriod of rapid brain growthBrain convolutions beginLungs begin to produce surfactantSensory brain waves begin to activateSensory brain waves begin to activateInner Ear Bones HardenBone marrow starts making blood cellsBone marrow starts making blood cellsBrown fat surrounds lymphatic systemFetal sexual organs visibleFinger and toe prints appearFinger and toe prints appearHeartbeat can be detectedHeartbeat can be detectedBasic Brain Structure in PlaceThe Appearance of SomitesFirst Detectable Brain WavesA Four Chambered HeartBeginning Cerebral HemispheresEnd of Embryonic PeriodEnd of Embryonic PeriodFirst Thin Layer of Skin AppearsThird TrimesterDevelopmental Timeline
Click weeks 0 - 40 and follow fetal growth
Search artcles published since 2007

June 13, 2012--------News Archive Return to: News Alerts


Tissue from a healthy mouse displaying "friendly' bacteria (purple)
on a patch of gut tissue, covered over with intestinal epithelial cells (
green).
Credit: Gregory Sonnenberg, PhD; David Artis, PhD,
Perelman School of Medicine University of Pennsylvania

WHO Child Growth Charts

What Is Your BMI?

       

Good Bugs, Bad Bugs

Bacteria that promote normal health can "turn bad" outside of the human intestine because our gut immune cells are needed to keep 'good' bacteria in their place

The healthy human intestine is colonized with over 100 trillion beneficial, or symbiotic — commensal — bacteria of many different species. In healthy people, these bacteria are limited to the intestinal tissues and have a number of helpful properties, including aiding in the digestion of food and promoting a healthy immune system.

However, when it comes to good bacteria, location is key. While good bacteria in the intestine provide positive effects, several chronic human diseases, including HIV/AIDS, inflammatory bowel disease, viral hepatitis, and obesity are associated with the spread of these intestinal good bacteria into the blood stream and other peripheral tissues, where they can cause chronic inflammation.

'Good bugs' that promote normal health can 'turn bad' if found in the wrong location.

In earlier work, researchers from the Perelman School of Medicine at the University of Pennsylvania found that barrier surfaces — the skin, gut, and lung — are guarded by immune cells and limit the inner body's exposure to viruses, bacteria, and parasites, as well as allergens and pollutants. But, how immune cells play a role in limiting the location of good bacteria to intestinal and other barrier sites remained unclear.

Now, David Artis, PhD, associate professor of Microbiology, and Gregory F. Sonnenberg, PhD, a postdoctoral researcher in the Artis lab, has identified that immune cells, called innate lymphoid cells, reside in the intestinal tissues of healthy humans, mice, and non-human primates, and are critical in limiting the location of good bacteria. If these innate lymphoid cells (immune cells) are reduced in mice, good bacteria move to peripheral tissues and promote inflammation.

The research appears this week in Science.

Remarkably, the good bacteria that were found in peripheral tissues were all members of a group called Alcaligenes, indicating that the immune system may have developed highly selective pathways to regulate containment of different groups of good bacteria.

"A fundamental question that has puzzled researchers for many years is how did the human body evolve to accommodate all these commensal bacteria and keep them in their correct locations?," asks Artis. "The indication from these studies is that the body may have many different pathways to limit the spread of commensal bacteria and these pathways may be tailored to specific types of bacteria."

Supporting experiments in animal models, Alcaligenes-specific immune responses were seen in patients with Crohn's disease or progressive hepatitis C virus infection, two debilitating human diseases linked to the spread of formerly good bacteria to systemic tissues.

"The identification of systemic Alcaligenes-specific immune responses in these patient populations suggests that, coupled with other groups of bacteria, the spread of Alcaligenes to tissues outside the intestine may be contributing to chronic inflammation and disease progression," suggests Sonnenberg.

Innate immune cells may become impaired in chronic human diseases, resulting in the spread of Alcaligenes bacteria and pathologic inflammation, which may represent a new way to target human disease, say the investigators.

"Although it's still early days for this line of research, these findings suggest that targeting innate lymphoid cell responses or directly targeting specific groups of commensal bacteria may be useful in the treatment of some chronic inflammatory diseases," adds Artis.

The research was funded by the National Institute of Allergy and Infectious Disease (AI061570, AI087990, AI074878, AI083480, AI095466, AI095608, T32-AI007532, T32-RR007063, K08-DK093784, AI47619); the NIH-funded Penn Center for AIDS Research (P30 AI 045008); the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award; the Philadelphia VA Medical Research and Merit Review; and the American Gastroenterological Association.

Co-authors in addition to Artis and Sonnenberg are Laurel A. Monticelli, Theresa Alenghat, Thomas C. Fung, Natalie A. Hutnick, Stephanie Grunberg, Rohini Sinha, Adam M. Zahm, Ronald G. Collman, Abraham Shaked, David B. Weiner, Joshua R. Friedman, Frederic D. Bushman, and Kyong-Mi Chang, all from Penn, as well as Jun Kunisawa, Naoko Shibata, and Hiroshi Kiyono from the University of Tokyo; Mélanie R. Tardif, and Philippe A. Tessier from Laval University; Lynette A Fouser from Pfizer Worldwide R&D; and Taheri Sathaliyawala, Masaru Kubota, and Donna L. Farber from Columbia University.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital — the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.

Original article: http://www.uphs.upenn.edu/news/News_Releases/2012/06/bugs/